Hidradenitis Suppurativa as a Paradoxical Side Effect to the Use of Adalimumab in Patients with Crohn’s Disease?

References

• Gomollón F, Dignass A, Annese V, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 1: diagnosis and medical management. J Crohns Colitis. 2017;11(1):3–25. doi:10.1093/ecco-jcc/jjw168
   PubMed Web of Science ®Google Scholar
• Samaan M, Campbell S, Cunningham G, Tamilarasan AG, Irving PM, McCartney S. Biologic therapies for Crohn’s disease: optimising the old and maximising the new. F1000 Res. 2019;8:1210. doi:10.12688/f1000research.18902.1
   Google Scholar
• Faivre C, Villani AP, Aubin F, et al. Hidradenitis suppurativa (HS): an unrecognized paradoxical effect of biologic agents (BA) used in chronic inflammatory diseases. J Am Acad Dermatol. 2016;74(6):1153–1159. doi:10.1016/j.jaad.2016.01.018
   PubMed Web of Science ®Google Scholar
• Delobeau M, Abdou A, Puzenat E, et al. Observational case series on adalimumab-induced paradoxical hidradenitis suppurativa. J Dermatolog Treat. 2016;27:251–253. doi:10.3109/09546634.2015.1094179
   PubMed Web of Science ®Google Scholar
• Salvador-Rodriguez L, Montero-Vílchez T, Arias-Santiago S, Molina-Leyva A. Paradoxical hidradenitis suppurativa in patients receiving TNF-α inhibitors: case series, systematic review, and case meta-analysis. Dermatology. 2020;236:307–313. doi:10.1159/000506074
   Web of Science ®Google Scholar
• Jemec GB. Clinical practice. Hidradenitis suppurativa. N Engl J Med. 2012;366(2):158–164. doi:10.1056/NEJMcp1014163
   PubMed Web of Science ®Google Scholar
• Yadav S, Singh S, Edakkanambeth Varayil J, et al. Hidradenitis suppurativa in patients with inflammatory bowel disease: a population-based cohort study in Olmsted County, Minnesota. Clin Gastroenterol Hepatol. 2016;14(1):65–70. doi:10.1016/j.cgh.2015.04.173
   PubMed Web of Science ®Google Scholar
• Phan K, Tatian A, Woods J, Cains G, Frew JW. Prevalence of inflammatory bowel disease (IBD) in hidradenitis suppurativa (HS): systematic review and adjusted meta-analysis. Int J Dermatol. 2020;59(2):221–228. doi:10.1111/ijd.14697
   PubMed Web of Science ®Google Scholar
• Alikhan A, Lynch PJ, Eisen DB. Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol. 2009;60(4):539–561. doi:10.1016/j.jaad.2008.11.911
   PubMed Web of Science ®Google Scholar
• Prens E, Deckers I. Pathophysiology of hidradenitis suppurativa: an update. J Am Acad Dermatol. 2015;73(5 Suppl 1):S8–S11. doi:10.1016/j.jaad.2015.07.045
   PubMed Web of Science ®Google Scholar
• Hurley H. Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa, and familial benign pemphigus: surgical approach. In: Roenigh RRH, editor. Dermatologic Surgery. New York: Marcel Dekker; 1989:729–739.
   Google Scholar
• Ellis LZ. Hidradenitis suppurativa: surgical and other management techniques. Dermatol Surg. 2012;38(4):517–536. doi:10.1111/j.1524-4725.2011.02186.x
   Web of Science ®Google Scholar
• Bohn J, Svensson H. Surgical treatment of hidradenitis suppurativa. Scand J Plast Reconstr Surg Hand Surg. 2001;35(3):305–309. doi:10.1080/028443101750523230
   Web of Science ®Google Scholar
• Alharbi Z, Kauczok J, Pallua N. A review of wide surgical excision of hidradenitis suppurativa. BMC Dermatol. 2012;12:9. doi:10.1186/1471-5945-12-9
   PubMedGoogle Scholar
• Matusiak L, Bieniek A, Szepietowski JC. Increased serum tumour necrosis factor-alpha in hidradenitis suppurativa patients: is there a basis for treatment with anti-tumour necrosis factor-alpha agents? Acta Derm Venereol. 2009;89(6):601–603. doi:10.2340/00015555-0749
   PubMed Web of Science ®Google Scholar
• Van der Zee HH, de Ruiter L, Van den Broecke DG, Dik WA, Laman JD, Prens EP. Elevated levels of tumour necrosis factor (TNF)-alpha, interleukin (IL)-1beta and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-alpha and IL-1beta. Br J Dermatol. 2011;164(2):1292–1298. doi:10.1111/j.1365-2133.2011.10254.x
   Web of Science ®Google Scholar
• Grant A, Gonzalez T, Montgomery MO, Cardenas V, Kerdel FA. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol. 2010;62(2):205–217. doi:10.1016/j.jaad.2009.06.050
   PubMed Web of Science ®Google Scholar
• Miller I, Lynggaard CD, Lophaven S, Zachariae C, Dufour DN, Jemec GB. A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa. Br J Dermatol. 2011;165(2):391–398. doi:10.1111/j.1365-2133.2011.10339.x
   PubMed Web of Science ®Google Scholar
• Dreno B, Khammari A, Brocard A, et al. Hidradenitis suppurativa: the role of deficient cutaneous innate immunity. Arch Dermatol. 2012;148(2):182–186. doi:10.1001/archdermatol.2011.315
   PubMedGoogle Scholar
• Giamarellos-Bourboulis EJ, Antonopoulou A, Petropoulou C, et al. Altered innate and adaptive immune responses in patients with hidradenitis suppurativa. Br J Dermatol. 2007;156(1):51–56. doi:10.1111/j.1365-2133.2006.07556.x
   PubMed Web of Science ®Google Scholar
• Cullen G, Kroshinsky D, Cheifetz AS, Korzenik JR. Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature. Aliment Pharmacol Ther. 2011;34(11–12):1318–1327. doi:10.1111/j.1365-2036.2011.04866.x
   PubMed Web of Science ®Google Scholar
• Wlodarczyk M, Sobolewska A, Wojcik B, Loga K, Fichna J, Wisniewska-Jarosinska M. Correlations between skin lesions induced by anti-tumor necrosis factor-alpha and selected cytokines in Crohn’s disease patients. World J Gastroenterol. 2014;20(22):7019–7026. doi:10.3748/wjg.v20.i22.7019
   PubMed Web of Science ®Google Scholar
• Zouboulis CC, Desai N, Emtestam L, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol. 2015;29(4):619–644. doi:10.1111/jdv.12966
   PubMed Web of Science ®Google Scholar
• Wolk K, Warszawska K, Hoeflich C, et al. Deficiency of IL-22 contributes to a chronic inflammatory disease: pathogenetic mechanisms in acne inversa. J Immunol. 2011;186(2):1228–1239. doi:10.4049/jimmunol.0903907
   PubMed Web of Science ®Google Scholar
• Van der Zee HH, Laman JD, de Ruiter L, Dik WA, Prens EP. Adalimumab (antitumour necrosis factor-alpha) treatment of hidradenitis suppurativa ameliorates skin inflammation: an in situ and ex vivo study. Br J Dermatol. 2012;166(2):298–305. doi:10.1111/j.1365-2133.2011.10698.x
   PubMed Web of Science ®Google Scholar
• Schlapbach C, Hanni T, Yawalkar N, Hunger RE. Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa. J Am Acad Dermatol. 2011;65(4):790–798. doi:10.1016/j.jaad.2010.07.010
   PubMed Web of Science ®Google Scholar